Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Stahel

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Cancer Treatment Reviews|December 24, 2014
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug developmentR Stahel, J Bogaerts, F Ciardiello, et al.
ESMO Open|August 21, 2022
Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countriesR Soo, L Mery, A Bardot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's LymphomaJ Lundin, A Osterborg, G Brittinger, et al.
ESMO Open|June 7, 2023
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trialN Girard, S Ponce Aix, S Cedres, et al.
The European Respiratory Journal|September 1, 2009
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesotheliomaA Scherpereel, P Astoul, P Baas, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 28, 2010
[Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma]A Scherpereel, P Astoul, P Baas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2020
Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trialS Hiltbrunner, C Britschgi, P Schuberth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 24, 2011
Third CECOG consensus on the systemic treatment of non-small-cell lung cancerT Brodowicz, T Ciuleanu, J Crawford, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2004
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomesT Le Chevalier, G Scagliotti, R Natale, et al.
British Journal of Cancer|April 20, 2006
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II studyD C Betticher, S-F Hsu Schmitz, M Tötsch, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Cancer Treatment Reviews|December 24, 2014
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug developmentR Stahel, J Bogaerts, F Ciardiello, et al.
ESMO Open|August 21, 2022
Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countriesR Soo, L Mery, A Bardot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's LymphomaJ Lundin, A Osterborg, G Brittinger, et al.
ESMO Open|June 7, 2023
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trialN Girard, S Ponce Aix, S Cedres, et al.
The European Respiratory Journal|September 1, 2009
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesotheliomaA Scherpereel, P Astoul, P Baas, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 28, 2010
[Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma]A Scherpereel, P Astoul, P Baas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2020
Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trialS Hiltbrunner, C Britschgi, P Schuberth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 24, 2011
Third CECOG consensus on the systemic treatment of non-small-cell lung cancerT Brodowicz, T Ciuleanu, J Crawford, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2004
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomesT Le Chevalier, G Scagliotti, R Natale, et al.
British Journal of Cancer|April 20, 2006
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II studyD C Betticher, S-F Hsu Schmitz, M Tötsch, et al.
Pageof 8